177,848 Shares in Omnicell, Inc. $OMCL Acquired by Nuveen LLC

Key Points

• Nuveen LLC acquired 177,848 shares of Omnicell, Inc., valued at approximately $6.2 million, representing about 0.38% of the company's shares as of its latest SEC filing.
• Omnicell's stock is currently priced at $33.09 with a market capitalization of $1.52 billion, while the stock price has seen a one-year range of $22.66 to $55.74.
• A number of analysts have raised their target prices for Omnicell, with Wells Fargo increasing its target from $37 to $40, rating the stock as "overweight."

Nuveen LLC purchased a new position in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 177,848 shares of the company's stock, valued at approximately $6,218,000. Nuveen LLC owned 0.38% of Omnicell at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of OMCL. Johnson Financial Group Inc. acquired a new stake in shares of Omnicell during the fourth quarter worth about $37,000. Point72 Hong Kong Ltd bought a new position in shares of Omnicell during the fourth quarter worth about $101,000. Corton Capital Inc. bought a new position in shares of Omnicell during the fourth quarter worth about $208,000. Caption Management LLC bought a new position in shares of Omnicell during the fourth quarter worth about $223,000. Finally, New Age Alpha Advisors LLC bought a new position in shares of Omnicell during the first quarter worth about $233,000. Institutional investors and hedge funds own 97.70% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on OMCL shares. Wall Street Zen downgraded Omnicell from a "strong-buy" rating to a "buy" rating in a report on Saturday, August 9th. Piper Sandler decreased their price objective on Omnicell from $57.00 to $55.00 and set an "overweight" rating for the company in a report on Monday, August 11th. Benchmark decreased their price objective on Omnicell from $62.00 to $40.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Bank of America increased their price objective on Omnicell from $30.00 to $34.00 and gave the stock a "neutral" rating in a report on Friday, May 23rd. Finally, Wells Fargo & Company increased their price objective on Omnicell from $37.00 to $40.00 and gave the stock an "overweight" rating in a report on Monday, July 21st. Four research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $46.71.

Omnicell Stock Performance

Shares of OMCL traded up $0.05 during mid-day trading on Thursday, reaching $33.28. The company's stock had a trading volume of 347,117 shares, compared to its average volume of 612,079. Omnicell, Inc. has a 1-year low of $22.66 and a 1-year high of $55.74. The stock has a market cap of $1.53 billion, a P/E ratio of 66.56, a PEG ratio of 7.26 and a beta of 0.78. The business has a 50-day simple moving average of $29.98 and a two-hundred day simple moving average of $31.68. The company has a current ratio of 1.42, a quick ratio of 1.24 and a debt-to-equity ratio of 0.13.

Omnicell (NASDAQ:OMCL - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The company reported $0.45 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.30 by $0.15. Omnicell had a return on equity of 4.27% and a net margin of 2.01%.The company had revenue of $290.56 million during the quarter, compared to analysts' expectations of $275.57 million. During the same period last year, the firm posted $0.51 earnings per share. The business's revenue was up 5.0% on a year-over-year basis. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS. As a group, equities research analysts anticipate that Omnicell, Inc. will post 1.09 earnings per share for the current fiscal year.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.